跳至主要内容
临床试验/EUCTR2016-003409-33-FI
EUCTR2016-003409-33-FI进行中(未招募)1 期

Optimizing 6-mercaptopurine therapy in paediatric acute lymphoblastic leukemia by using allopurinol - Allopurinol in maintenance

Queen Silvias Childrens and Adolescents Hospital0 个研究点目标入组 60 人开始时间: 2018年5月16日最近更新:
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • All children with standard or intermediate risk acute lymphoblastic leukemia, aged 0-18 years at time of diagnosis of leukemia and treated according to ALL2008 protocols and with TPMT wild type who start maintenance 2 phase are eligible.
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range: 60
  • F.1.2 Adults (18-64 years) no
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • -Mature B celL lymphoblastic leukemia; t(9;22) positive acute lymphoblastic leukemia
  • -Unknown TPMT status or presence of TPMT mutation (both heterozygous and homozygous)
  • -Known intolerance to any of the chemotherapeutic drugs in the protocol
  • -Major organ failure precluding administration of planned chemotherapy
  • -Sever liver toxicity defined as persistent (= two weeks) elevation of either S-bilirubin > 50 ??mol/l or S-GPT > 20 x UNL (upper normal limit) or P-Protrombin complex > 1.5
  • -Reduced kidney function defined as S creatine = 2 x UNL
  • -Lactating female or female of childbearing potential not using adequate contraception

研究者

发起方
Queen Silvias Childrens and Adolescents Hospital

相似试验